OUE

OUE HEALTHCARE

OUE Limited's Proposed Privatisation of OUE Healthcare Limited

Investor Presentation

24 August 2026

Disclaimer

THIS PRESENTATION SHALL NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY SECURITIES IN ANY JURISDICTION, INCLUDING IN THE UNITED STATES OF AMERICA OR ELSEWHERE.

This presentation should be read in conjunction with the joint announcement released by OUE Healthcare Limited ("**Company**") and Treasure International Holdings Pte. Ltd. ("**Offeror**") (a wholly-owned subsidiary of OUE Limited ("**OUEL**")) on 24 August 2026 relation to the proposed acquisition (the "**Acquisition**") of all the issued and paid-up ordinary shares in the capital of the Company (the "**Shares**") (other than the Shares held by the Offeror) by the Offeror from the shareholders of the Company (other than the Offeror). The Acquisition will be effected by the Company by way of a scheme of arrangement in accordance with Section 210 of the Companies Act 1967 of Singapore and the Singapore Code on Take-overs and Mergers.

A copy of the Joint Announcement is available on https://www.sgx.com/securities/company-announcements and the websites of OUEL and the Company.

In the event of any inconsistency or conflict between the Joint Announcement and the information contained in this presentation, the Joint Announcement shall prevail. All capitalised terms not defined in this presentation shall have the meaning ascribed to them in the Joint Announcement.

All statements other than statements of historical facts included in this presentation are or may be forward-looking statements. Forward-looking statements include but are not limited to those using words such as "seek", "expect", "anticipate", "estimate", "believe", "intend", "project", "plan", "strategy", "forecast" and similar expressions or future or conditional verbs such as "will", "would", "should", "could", "may" and "might". Actual future performance, outcomes and results may differ materially from those expressed in forward-looking statements as a result of a number of risks, uncertainties and assumptions. Representative examples of these factors include (without limitation) general industry and economic conditions, interest rate trends, cost of capital and capital availability, competition from similar developments, shifts in expected levels of occupancy or property rental income, changes in operating expenses (including employee wages, benefits and training costs), governmental and public policy changes and the continued availability of financing in amounts and on terms necessary to support future business. Any such forward-looking statements reflect various beliefs and assumptions concerning anticipated economic and competitive uncertainties and contingencies, many of which are beyond the control of the Company, the Offeror and OUEL. Accordingly, there can be no assurance that such projections and forward-looking statements will be realised, whether in whole or in part.

Given the risks and uncertainties that may cause actual results or outcomes to differ materially from those expressed or implied in such forward-looking statements, shareholders and investors in the Company should not place undue reliance on such forward-looking statements. None of the Company, the Offeror or OUEL undertakes any obligation to update publicly or revise any forward-looking statements or financial information contained in this presentation to reflect any change in the Company, the Offeror or OUEL's expectations with regard thereto or any change in events, conditions or circumstances on which any such statement or information is based, subject to compliance with all applicable laws and regulations and/or the rules of the Singapore Exchange Securities Trading Limited and/or any other regulatory or supervisory body or agency.

The past performance of the Company is not necessarily indicative of the future performance of the Company. This presentation is for information purposes only and does not have regard to your specific investment objectives, financial situation or your particular needs. It does not purport to be all-inclusive or to contain all of the information that a person considering the proposed transaction described herein may require to make a full analysis of the matters referred to herein. Any information in this presentation is not to be construed as investment or financial advice.

This presentation has not been reviewed by the Monetary Authority of Singapore.

Any discrepancies in the figures included herein between the listed amounts and total thereof are due to rounding.

Save to the extent set out in the respective Directors' Responsibility Statements set out on page 13, no representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information contained herein and no reliance should be placed on it. None of the Company, the Offeror, OUEL or any of their affiliates or their advisers, connected persons or any other person accepts any liability for any loss howsoever arising (in negligence or otherwise), directly or indirectly, from this presentation or its contents or otherwise arising in connection with this presentation.

Scheme Shareholders are advised to wait for and to consider the full details in the Scheme Document (which will also contain recommendations from the Company's Recommending Director(s) and advice of the IFA on the Scheme) before taking any action in relation to their Scheme Shares.

Transaction Overview

Offeror	➢ Treasure International Holdings Pte. Ltd. (the "**Offeror**"), which is a wholly owned subsidiary of OUE Limited
Transaction Structure	➢ Privatisation of OUE Healthcare Limited (the "**Company**"), to be effected through: the proposed acquisition (the "**Acquisition**") of all the issued and paid-up ordinary shares in the capital of the Company (the "**Shares**") (other than the Shares held by the Offeror) (the "**Scheme Shares**") by the Offeror from the shareholders of the Company (other than the Offeror), by way of a scheme of arrangement (the "**Scheme**") in accordance with Section 210 of the Companies Act 1967 of Singapore (the "**Companies Act**") and the Singapore Code on Take-overs and Mergers (the "**Code**")
Scheme Consideration	➢ **S$ 0.050** in cash per Scheme Share (the "**Scheme Consideration**")
Key Approvals Required	➢ **Scheme Meeting** - the approval of the Scheme by a majority in number of the Scheme Shareholders(1) representing not less than three-fourths in value of the Scheme Shares held by Scheme Shareholders present and voting either in person or by proxy at the Scheme Meeting(2) ➢ **Court sanction** for: (i) convening the Scheme Meeting; and (ii) the approval of the Scheme (following approval by the Scheme Shareholders at the Scheme Meeting) ➢ **Clearance from the Sponsor of the Scheme Document and approval-in-principle from the Singapore Exchange Securities Trading Limited** ("**SGX-ST**") for the proposed delisting of the Company from the Catalist Board of the SGX-ST after the Scheme becomes effective and binding in accordance with its terms

Note:
(1) Scheme Shareholders refers to the holders of the Scheme Shares.
(2) The Offeror and its concert parties (the "Offeror Concert Party Group") and the common substantial shareholders of the Offeror Concert Party Group will abstain from voting on the Scheme.

1

Rationale for the Scheme

Rationale for the Scheme

OUE | OUE HEALTHCARE

1 Opportunity for Scheme Shareholders to realise their entire investment in cash at a compelling price and favourable valuation without incurring brokerage costs

An opportunity for the Scheme Shareholders to realise their investment in the Shares at a compelling premium of:

- 36.1% - 51.1% over the historical volume weighted average price[1]
- 2.5% premium to the latest unaudited NAV per Share as at 30 June 2026
- The Scheme Consideration is higher than the closing share price of the Shares in the past five (5)-year period up to the Last Trading Day

2 Opportunity for Scheme Shareholders to exit their entire investment in the Scheme Shares, which may otherwise be difficult due to low trading liquidity of the Shares

	One-month	Three-month	Six-month	Twelve-month
Average daily trading volume as a percentage of total number of Shares[2]	0.06%	0.12%	0.07%	0.05%

Due to the low trading liquidity of the Shares, over the last 12-month period, there were 16 market days[2] when the Shares did not trade on the SGX-ST

3 Greater management flexibility to focus on longer-term business strategies

- This provides the Offeror and the Company's management with greater flexibility to manage and grow the existing business of the Company
- The Company’s China operations are currently ramping up and may require time to stabilize. By privatising the Company, it will enable management to pursue longer-term business strategies which may otherwise contrast or conflict with the shorter-term expectations of the public market

4 Compliance cost of maintaining listing

- Eliminate ongoing listing, regulatory, reporting, and investor communication requirements, resulting in cost savings
- Allows it to redirect resources from compliance and listing maintenance toward its business operations

Notes:
(1) Rounded to the nearest one decimal place.
(2) As of 21 August 2026.
Source: Bloomberg

2

Financial Evaluation of the Scheme Consideration

Share Price of the Company in the Last 5 Years

The Scheme Consideration is higher than the closing share price of the Shares in the past five (5)-year period up to and including the Last Trading Day

Share price (S$)



- The Scheme Consideration of **S$ 0.050 per Scheme Share** represents a premium of 28.2%, 37.5%, 36.1%, 42.1%, and 51.1%, to the Company's Last Transacted Price, 1-month, 3-month, 6-month and 12-month VWAP
- The Scheme Consideration is higher than the closing share price of the Shares in the past five (5)-year period

Source(s): Bloomberg and Capital IQ as at 21 August 2026.

Premium to Historical Prices

Scheme Consideration is at a premium[1] to the Last Transacted Price, one (1)-month, three (3)-month, six (6)-month and 12-month historical VWAPs[2] and at a premium to the latest unaudited NAV per Share as at 30 June 2026



Notes:
(1) Rounded to the nearest one decimal place.
(2) As of 21 August 2026.
Source: Bloomberg

OUEH's Low Trading Liquidity and Attractive Privatisation Premium Support the Rationale for Privatisation

Precedent Catalist healthcare privatisation transactions over the last 5 years

12-month Average Daily Trading Volume (% of Total Shares Outstanding)[1]



Persistently Low Liquidity

- The low trading liquidity profile of the Shares, significantly below the STI benchmark, is consistent with that of other Catalist healthcare sector issuers which have been privatised in recent years

OUEH's Proposed Privatisation Premium vs. Precedent Catalist Healthcare Privatisations Across Historical Trading Levels



Attractive Premium to Historical Trading Levels

- Against a backdrop of low trading liquidity in the Company's Shares (and other Catalist healthcare issuers which has been privatised in recent years), the Offeror believes that the Scheme Consideration of S$0.050 per Scheme Share represents an attractive opportunity for Scheme Shareholders to realise their investment in the Company at a price which exceeds the average premium observed in precedent Catalist healthcare privatisations on the SGX-ST

Note: (1) Calculated using the total volume of shares traded during 12-months to announcement date divided by the number of market days on which shares were traded on SGX-ST; (2) Calculated using the total aggregated traded volume of STI constituents divided by the aggregated total number of shares outstanding of the last 12 months; (3) Refers to Singapore Medical Group; (4) Refers to Asian Healthcare Specialists; (5) Refers to Straits Times Index
Sources: Bloomberg as at 21 August 2026

3

Approvals Required and Timeline

The Scheme is Subject to Approval of Scheme Shareholders and Other Conditions

Approval Threshold for the Scheme

Head Count Condition		Share Value Condition
>50% More than 50% of the Scheme Shareholders present and voting either in person or by proxy at the Scheme Meeting must vote to approve the Scheme	And	**≥75%** Scheme Shareholders representing at least 75% in value of the Scheme Shares held by the Scheme Shareholders present and voting either in person or by proxy at the Scheme Meeting must vote to approve the Scheme

The Offeror and its concert parties, and the common substantial shareholders of the Offeror and its concert parties on one hand, and the Company on the other, will abstain from voting on the Scheme and will also decline to accept appointment as proxy from any Scheme Shareholders to vote on the Scheme.

Other Approvals	Requirements
Court and Regulatory Approvals	➢ Court order sanctioning: (1) the convening of the Scheme Meeting; and (2) the Scheme (following approval by the Scheme Shareholders at the Scheme Meeting) ➢ Satisfaction of regulatory approvals including (i) clearance from the Sponsor of the Scheme Document and (ii) approval-in-principle from the SGX-ST for the proposed delisting of the Company from the Catalist Board of the SGX-ST after the Scheme becomes effective and binding in accordance with its terms

Indicative Transaction Timetable

Indicative Date	Events
24 August 2026	Joint Announcement of Scheme
Mid October 2026	Expected date of first Court hearing(1) to convene the Scheme Meeting
End October 2026	Expected date of dispatch of Scheme Document and notice of Scheme Meeting
Mid November 2026	Expected date of Scheme Meeting(1) for Scheme Shareholders
End December 2026	Expected Effective Date of the Scheme/Completion(2)
Early January 2027	Expected delisting of the Company from Catalist Board of the SGX-ST

The timeline above is indicative only and subject to change.
The exact dates of these events will be announced on SGXNET by the Company and/or the Offeror.

Notes:
(1) The dates of the Court hearings of the application to (i) convene the Scheme Meeting; and (ii) approve the Scheme will depend on the dates that are allocated by the Court.
(2) The Scheme will become effective upon the lodgement of the Scheme Court Order in accordance with Section 210(5) of the Companies Act with the Accounting and Regulatory Authority of Singapore.

Investor Contact

For any enquires relating to the Scheme, please contact the below

Financial Adviser to the Offeror in respect of the Acquisition and the Scheme

Maybank Securities Pte. Ltd.

Investment Banking & Advisory

T: +65 6231 5978

OUE Limited Investor Relations

T: +65 6809 6064

E: investorrelations@oue.com.sg

OUE Healthcare Limited Investor Relations

Citigate Dewe Rogerson Singapore Pte. Ltd.

T: +65 6534 5122

Responsibility Statement

Treasure International Holdings Pte. Ltd. -

The directors of the Offeror (including any who may have delegated detailed supervision of the preparation of this presentation) have taken all reasonable care to ensure that the facts stated and all opinions expressed in this presentation which relate to the Offeror (excluding information relating to the Company or any opinion expressed by the Company) are fair and accurate and that there are no other material facts not contained in this presentation, the omission of which would make any statement in this presentation misleading. The directors of the Offeror jointly and severally accept responsibility accordingly.

Where any information has been extracted or reproduced from published or otherwise publicly available sources or obtained from the Company, the sole responsibility of the directors of the Offeror has been to ensure that, through reasonable enquiries, such information is accurately extracted from such sources or, as the case may be, reflected or reproduced in this presentation. The directors of the Offeror do not accept any responsibility for any information relating to the Company or any opinion expressed by the Company.

OUE Healthcare Limited -

The directors of the Company (including any who may have delegated detailed supervision of the preparation of this presentation) have taken all reasonable care to ensure that the facts stated and all opinions expressed in this presentation which relate to the Company (excluding information relating to the Offeror or any opinion expressed by the Offeror) are fair and accurate and that there are no other material facts not contained in this presentation, the omission of which would make any statement in this presentation misleading. The directors of the Company jointly and severally accept responsibility accordingly.

Where any information has been extracted or reproduced from published or otherwise publicly available sources or obtained from the Offeror, the sole responsibility of the directors of the Company has been to ensure that, through reasonable enquiries, such information is accurately extracted from such sources or, as the case may be, reflected or reproduced in this presentation. The directors of the Company do not accept any responsibility for any information relating to the Offeror or any opinion expressed by the Offeror.

Sponsor's Statement

This presentation has been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. (the "**Sponsor**"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "**Exchange**") and the Exchange assumes no responsibility for the contents of this presentation, including the correctness of any of the statements or opinions made or reports contained in this presentation.

The contact person for the Sponsor is Ms. Foo Jien Jieng, 16 Collyer Quay, #10-00 Collyer Quay Centre, Singapore 049318, sponsorship@ppcf.com.sg.

OUE

OUE HEALTHCARE

THANK YOU